This investor loves Boston Scientific

Velocity Investment Counsel portfolio manager Brianne Gardner told BNN Bloomberg’s Market Call on Nov. 28 that Boston Scientific (Boston Scientific Stock Quote, Chart, News, Analysts, Financials NYSE:BSX) remains well-positioned as demand for less-invasive cardiac and chronic-pain treatments accelerates.

Gardner said Boston Scientific is benefiting from a clear shift in patient and hospital preferences.

“They make less invasive devices for heart issues and chronic pain — exactly where patient demand is moving,” she said, adding that the company “is becoming a leader in treating irregular heartbeats.”

She also pointed to improvements in its stroke-prevention device portfolio, noting that “new versions are coming out” and hospitals are increasingly choosing the company’s solutions.

She described Boston Scientific’s financial profile as “solid,” citing strong margins that support continued investment in R&D and long-term product pipeline expansion. With an aging population driving higher baseline demand for cardiovascular and neurological care, Gardner sees a steady expansion of the company’s addressable market. She rated the name “eight out of 10” internally and sees “about 26% upside from here with a price target of about 128.”

Asked about global reach, Gardner said Boston Scientific already operates worldwide and continues to expand through partnerships and market entries abroad.

“They are global… and continue to expand into global markets,” she said, adding that broader exposure should create additional growth opportunities over time.

Boston Scientific shares are up 12.0% over the past 12 months. Among covering analysts, 36 rate the stock “Buy,” one “Hold” and none “Sell,” with a consensus target of US$126.77.

-30-